Citigroup’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Citigroup’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Hold	0	–	-$1K	–	6444
2022 Q2	–	Sell	-14	Closed	-$36.5K	–	6124
2022 Q1	$45K	Buy	14 +7	+100%	+$30.1K	﹤0.01%	4772
2021 Q4	$41K	Buy	7 +4	+133%	+$30.7K	﹤0.01%	5165
2021 Q3	$28K	Buy	3 +2	+200%	+$17.2K	﹤0.01%	5075
2021 Q2	$10K	Buy	+1	New	+$16.4K	﹤0.01%	5678
2018 Q1	–	Hold	0	–	-$4K	–	7706
2017 Q4	–	Hold	0	–	–	–	7294
2017 Q3	–	Hold	0	–	–	–	6976
2016 Q2	–	Hold	0	–	-$1K	–	7503
2016 Q1	–	Hold	0	–	–	–	7350
2015 Q4	–	Hold	0	–	–	–	7431
2015 Q3	–	Hold	0	–	–	–	7241
2015 Q2	–	Hold	0	–	–	–	7168
2015 Q1	–	Hold	0	–	–	–	6964
2014 Q4	–	Hold	0	–	–	–	6811
2014 Q3	–	Hold	0	–	–	–	6667
2014 Q2	–	Hold	0	–	–	–	6399
2014 Q1	–	Hold	0	–	–	–	6602
2013 Q4	–	Hold	0	–	–	–	6246
2013 Q3	–	Hold	0	–	–	–	6419
2013 Q2	–	Hold	0	–	–	–	6282

Other funds holding SEEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Citigroup's SEEL Position: Q3 2022 in Review

Citigroup held its Seelos Therapeutics, Inc. Common Stock (SEEL) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6444.

Citigroup first reported a position in SEEL in Q2 2021 and has held it in 4 quarters since. The position peaked at $45K in Q1 2022. 68 funds tracked by Wall St. Rank hold SEEL as of Q3 2022.

Citigroup held 0 shares of Seelos Therapeutics, Inc. Common Stock worth $0 as of Q3 2022.
Citigroup left its Seelos Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
Seelos Therapeutics, Inc. Common Stock made up ﹤0.01% of Citigroup's portfolio in Q3 2022, its #6444 holding.
Citigroup first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and has held it in 4 quarters since.
Citigroup's Seelos Therapeutics, Inc. Common Stock position peaked at $45K in Q1 2022.
68 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.